Biosynexus Incorporated
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Biosynexus Incorporated sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Biosynexus Incorporated: 4 sponsored US clinical trials, none currently recruiting.
Biosynexus Incorporated sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Staphylococcal Sepsis, with 1 trials.
Upper-quartile sponsor footprint
Biosynexus Incorporated sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis
NCT00646399
Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110
NCT00631800
Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110
NCT00631878
Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants
NCT00636285
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Therapeutic Areas
How the Biosynexus Incorporated early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 4 completed (100%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Staphylococcal Sepsis (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Biosynexus Incorporated: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Biosynexus Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Biosynexus Incorporated page
4 registered trials is a research-attention snapshot, not an endorsement of Biosynexus Incorporated or any single study.
- None of Biosynexus Incorporated's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Staphylococcal Sepsis is the condition Biosynexus Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Staphylococcal Sepsis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Biosynexus Incorporated pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.